(NASDAQ: NERV) Minerva Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.46%.
Minerva Neurosciences's earnings in 2026 is -$415,074,589.On average, 5 Wall Street analysts forecast NERV's earnings for 2026 to be -$89,576,111, with the lowest NERV earnings forecast at -$162,995,257, and the highest NERV earnings forecast at -$9,783,629. On average, 5 Wall Street analysts forecast NERV's earnings for 2027 to be -$24,710,651, with the lowest NERV earnings forecast at -$43,374,088, and the highest NERV earnings forecast at -$4,402,633.
In 2028, NERV is forecast to generate -$31,554,533 in earnings, with the lowest earnings forecast at -$67,935,655 and the highest earnings forecast at $7,826,903.